In 2006, a remarkable collaboration between University of Texas MD Anderson Cancer Center clinicians and Texas and New Mexico State legislators led to the formation of a dedicated IBC Research Program and Clinic at MD Anderson. This initiative provided funding and infrastructure to foster coordination of an IBC World Consortium of national and international experts, and launch the first ever IBC international conference in 2008, which brought together experts from around the world to facilitate collaborations and accelerate progress. Indeed great progress has been made since then. National and international experts in IBC convened at the 10 Anniversary Conference of the MD Anderson IBC Clinic and Research Program and presented the most extensive sequencing analysis to date comparing IBC to non-IBC, gene- and protein-based immunoprofiling of IBC non-IBC patients, and converging lines of evidence on the specific role of the microenvironment in IBC. Novel models, unique metabolic mechanisms, and prominent survival pathways have been identified and were presented. Multiple clinical trials based on the work of the last decade are in progress or in development. The important challenges ahead were discussed. This progress and a coordinated summary of these works are presented herein.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687177 | PMC |
http://dx.doi.org/10.7150/jca.21200 | DOI Listing |
Subst Use Misuse
December 2024
Dirección de Investigación y Enseñanza, Centros de Integración Juvenil AC, Ciudad de México, México.
Objectives: Tobacco smoking remains a major public health risk, responsible for millions of deaths worldwide. While smoking patterns in Mexico differ from those in countries with higher rates, comorbidities such as diabetes pose a health risk. Although many smokers want to quit, access to cessation services is limited.
View Article and Find Full Text PDFJ Exp Clin Cancer Res
December 2024
Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, SC, USA.
Ductal carcinoma in situ (DCIS) is a noninvasive breast disease that variably progresses to invasive breast cancer (IBC). Given the unpredictability of this progression, most DCIS patients are aggressively managed similar to IBC patients. Undoubtedly, this treatment paradigm places many DCIS patients at risk of overtreatment and its significant consequences.
View Article and Find Full Text PDFJCO Glob Oncol
December 2024
Early Drug Development for Innovative Therapies Division, European Institute of Oncology, IRCCS, Milan, Italy.
Purpose: Trimodal therapy (TMT) is the standard treatment for patients with nonmetastatic inflammatory breast cancer (IBC). TMT consists of neoadjuvant systemic therapy, modified radical mastectomy (MRM), and postmastectomy radiation therapy. Although broadly considered the best approach for IBC, in the United States, only a third of patients receive TMT.
View Article and Find Full Text PDFQuant Imaging Med Surg
December 2024
Department of Ultrasound, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University), Shenzhen, China.
Background: Preoperative ultrasound-guided core needle biopsy (CNB) is currently the standard procedure for managing breast illnesses. However, the differences in outcomes between CNB and surgical excision (SE) have not been thoroughly assessed. This study aimed to explore the disparities in pathological outcomes between these two procedures, using a large sample dataset.
View Article and Find Full Text PDFEJNMMI Radiopharm Chem
December 2024
Department of Nuclear Engineering, University of Tennessee, Knoxville, Knoxville, TN, 37996, USA.
Background: Neuroendocrine tumors (NETs) are clinically diverse types of tumors that can arise anywhere in the body. Previous studies have shown that somatostatin receptors (SSTRs) are overexpressed on NET cell membranes relative to healthy tissue, allowing for tumor targeting through radiolabeled somatostatin analogs (SSAs). This work aims to develop a novel Zr-labeled tracer incorporating the SSA, octreotide (TOC), for positron emission tomography (PET) imaging of SSTR + NETs and predictive dosimetry calculations, leveraging the excellent nuclear (t = 3.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!